BioTuesdays

Category - News

Vericel Logo
Markets

Ladenburg ups Vericel to buy; PT $13

Ladenburg Thalmann upgraded Vericel (NASDAQ:VCEL) to “buy” from “neutral” and introduced a price target of $13. The stock closed at $9.10 on July 13. “We believe Vericel shares are oversold and would be buyers of the...

July 16, 2018
Galmed Logo
Markets

Stifel starts Galmed Pharma at buy; PT $35

Stifel launched coverage of Galmed Pharmaceuticals (NASDAQ:GLMD) with a “buy” rating and price target of $35. The stock closed at $12.77 on July 12. “We think Galmed’s lead, wholly-owned asset, Aramchol, has...

July 13, 2018
Syndax Pharma Logo
Markets

HCW starts Syndax Pharma at buy; PT $30

H.C. Wainwright initiated coverage of Syndax Pharmaceuticals (NASDAQ:SNDX) with a “buy” rating and a $30 price target. The stock closed at $7.10 on July 11. Analyst Edward White writes that Syndax’s lead candidate...

July 12, 2018
Profound Medical Logo
Developments

Profound Medical uplisting to TSX

Profound Medical (TSXV:PRN; OTCQX:PRFMF) has received final approval to list its common shares on the Toronto Stock Exchange, effective at the opening on July 13, 2018. The stock will continue to trade under the symbol...

July 11, 2018
exicure logo
Markets

Ladenburg starts Exicure at buy; PT $18

Ladenburg Thalmann launched coverage of Exicure (OTCQB:XCUR) with a “buy” rating and $18 price target. The stock closed at $5.65 on July 10. Exicure is developing first-in-class spherical nucleic acid (SNA)...

July 11, 2018
Krystal Biotech Logo
Markets

Leerink starts Krystal Biotech at buy; FVE $29

Leerink launched coverage of Krystal Biotech (NASDAQ:KRYS) with a “buy” rating and $29 fair value estimate. The stock closed at $15.07 on July 9. Krystal is developing novel gene therapies for skin diseases, with lead...

July 10, 2018
Rocket Pharmaceuticals Logo
Markets

WB starts Rocket Pharma at OP; FVE $32

William Blair launched coverage of Rocket Pharmaceuticals (NASDAQ:RCKT) with an “outperform” rating and fair value estimate of $32. The stock finished at $19.17 on July 9. Rocket is focused on developing first-in-class...

July 10, 2018
ContraFect Logo
Markets

Ladenburg starts ContraFect at buy; PT $3

Ladenburg Thalmann initiated coverage of ContraFect (NASDAQ:CFRX) with a “buy” rating and $3 price target. The stock closed at $2.59 on July 9. “We view ContraFect as a biologics story with a potential first-in-class...

July 10, 2018